Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Gross Margin (2016 - 2025)

Haemonetics has reported Gross Margin over the past 17 years, most recently at 59.71% for Q4 2025.

  • Quarterly results put Gross Margin at 59.71% for Q4 2025, up 418.0% from a year ago — trailing twelve months through Dec 2025 was 59.35% (up 607.0% YoY), and the annual figure for FY2025 was 55.04%, up 221.0%.
  • Gross Margin for Q4 2025 was 59.71% at Haemonetics, roughly flat from 59.5% in the prior quarter.
  • Over the last five years, Gross Margin for HAE hit a ceiling of 59.82% in Q2 2025 and a floor of 36.35% in Q2 2021.
  • Median Gross Margin over the past 5 years was 53.21% (2022), compared with a mean of 53.05%.
  • Biggest five-year swings in Gross Margin: plummeted -1126bps in 2021 and later soared 1508bps in 2022.
  • Haemonetics' Gross Margin stood at 51.08% in 2021, then grew by 2bps to 51.98% in 2022, then grew by 2bps to 52.9% in 2023, then increased by 5bps to 55.53% in 2024, then increased by 8bps to 59.71% in 2025.
  • The last three reported values for Gross Margin were 59.71% (Q4 2025), 59.5% (Q3 2025), and 59.82% (Q2 2025) per Business Quant data.